Mehdi Shahidi joins Lakefront Biotherapeutics NV Board of Directors
What happened
Mehdi Shahidi was appointed as a Non-Executive Independent Director to the Board of Directors of Lakefront Biotherapeutics NV, effective November 2, 2026. He replaced Dr. Paulo Fontoura, who resigned from the Board in July 2026. Shahidi is a physician-scientist with over 20 years of biopharma experience in drug development and regulatory affairs.
From manilatimes.net
Why it matters
Gino Santini, Chair of the Board of Directors, stated that Shahidi’s background in drug development and regulatory success will strengthen the Board’s strategic guidance. This guidance is intended to support Lakefront Biotherapeutics NV as it advances its gamgertamig and preclinical assets while managing its strategic capital.
From manilatimes.net
Who's involved
- board of directorsThe governing body that oversees the activities of Lakefront Biotherapeutics NV.
- companyThe biopharmaceutical company that appointed Mehdi Shahidi to its Board of Directors.
- Charlie ColeThe director who previously served on the Board of Directors before resigning.
- JudyThe Chair of the Board of Directors, who welcomed Mehdi Shahidi.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- companySpeculative
Lakefront Biotherapeutics NV might see its investment decisions and strategic capital deployment costs influenced by the new Board of Directors' expertise.
Keep exploring
The entities involved
-
board of directors
group of people who jointly supervise the activities of an organization